CANCER SCREENING & TREATMENT CENTER OF NEVADA
CENTURY WELLNESS CLINIC

Presents
Outcome Based
POLY-MVA CLINICAL STUDY
2004

POLY- MVA: THE PRODUCT

1. POLY- A patented palladium lipoic acid complex
2. MVA: Minerals: Molybdenum, Rhodium & Ruthenium
   Vitamins: B1, B2, B12
   Amino Acids: Formyl-Methionine, N-acetyl cysteine,
3. Palladium (PL) is a rare mineral often combined with platinum in jewelry. M.W. 106 found in nature alloyed with platinum,copper and nickel. Highly conductive metal.
4. ALA a super antioxidant and detoxifier. It is both water and fat soluble. It is an effective chelator with heavy metals.

POLY- MVA: PROVEN ACTIONS

1. Aid in cellular energy production
2. Support liver detoxification
3. Protect cell integrity
4. Acts as a heavy metal chelator
5. Acts as a powerful antioxidant
6. Support nerve and neurotransmittal function
7. Enhance WBC function
8. Assists in improving energy flow along meridians

• The original family member of palladium lipoic complex, DNA Reductase, was named for its ability to shunt electron energy from itself to DNA via the mitochondria. [By donating electrons DNA can be reduced, and thus oxidation in general , as well as a result of radiation and carcinogens, can be combated.]
• The mineral Palladium was chosen for a specific reason. For one it has a common resonance frequency with DNA whereby electron transfer between the molecules is facilitated. Also, Palladium can be permanently bound to alpha lipoic acid.
• Palladium Lipoic acid (LAPd) complex’s differ from free radical scavengers (e.g. ?lipoic acid) because they are irreversibly bound together resulting in a molecule that is both fat and water soluble. Poly MVA is a polymer (liquid crystal) rather than a single molecule. Therefore, the polymer provides a unified redox (will accept charge and donate charge) reaction.

• Their ability to both quench radical species and shunt electrons down the electron transport chain also make them effective in limiting ischemic damage (Antonawich, et al., Experimental Neurology, 2004; Antonawich and Welicky).
• While it has the ability to shuttle energy to each cell, the selective vulnerability of the cancer cell is due to its disrupted metabolic STATE.
• Safety data, including Ames and toxicity tests has been done and has shown complete safety. (Pharmakon and Calvert Labs)

POLY- MVA: PROTOCOL

POLY- MVA: CLINICAL TRIAL

• Overall Response Rates (ORR)
• ORR minus early expirations, discontinuations, too early to evaluate
• Complete responses (CR) 14/66 = 21%
• Partial Responses (PR) 39/66 = 56%
• Overall Response Rate (ORR) CR + PR = 77%
• Progressive Disease (PD) = 23%

POLY-MVA PROTOCOL BY TUMOR TYPE

TOTAL NUMBER OF CASES 106

POLY-MVA PROTOCAL
TUMOR RESPONSE RATES OF FOUR MAJOR CANCERS

IV POLY-MVA RESULTS

POLY-MVA CLINICAL PROTOCOL SAMPLE CASES

• This Clinical Oncology “Outcome Based” study over a nine month period was conducted on Stage IV patients with multiple cancer origins.
• The Study was voluntary and not double-blinded or placebo controlled.
• The major parameters included:

  CR – All Clinical disease in Remission

  PR – Greater than 50% reduction in tumor mass/markers

  PD – Progressive disease, no cessation in tumor growth

• A 77% overall response rate (ORR) combining CR +PR > 3months
• No significant adverse toxicities-IV or oral.
• Significant response rate in patients not on conventional chemotherapy or hormonal therapy – 42%

Palladium Lipoic Acid (PLA) acts by transferring electron charge from membrane fatty acids to DNA and mitochondria. Approximately a quarter volt of energy is utilized by the mitochondria, of normal cells, to combine with oxygen to form water in coupled reactions to produce energy (ATP) for normal growth and healing.

In anaerobic or severely hypoxic cell systems, however, such as in certain malignant tumors and protozoa, the electron energy can not transfer to mitochondrial oxygen. Instead a sequence of ionization begins in the cell membrane and in the mitochondrial membrane. These ionization reactions begins with membrane blebbing and matures into a cascade of reactions, known collectively as apoptosis, in which mitochondrial proteins are released, facilitating the activation of cell destructive enzymes. These reactions lead to the eventual death of the anaerobic or hypoxic (cancer) cell and provide a theoretical model for treatment studies.

Over 800 physicians who use Poly-MVA cannot be wrong. Dr. James Forsythe, Board Certified Oncologist has recently presented his 125 case study of stage 4 cancer patients with a 77 percent response rate using Poly-MVA. Non-Hodgkins Lymphoma, Ovarian, Brain, Pancreatic, Breast, Multiple Myeloma, Leukemia and Lung cancers, many with wide metastasis responded. A 23 percent FULL REVERSAL statistic is unheard of in these type of cancers, add to that 54 percent who had partial remissions and improving and you have a miracle in the making. All this with an average of 6 months of treatment. Yes that is what Dr. Forsythe reported – 77 percent response rate in terminal patients! Are you ready to assist the many cancer patients in your practice by using a non-toxic discovery ?